NCT07908888
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
2-year progression-free survival (PFS) rate
Timeframe: 2 years
Arms and interventions
Pola-R-miniCHPExperimental
Participants receive polatuzumab vedotin and rituximab combined with reduced-dose cyclophosphamide, doxorubicin and prednisone (Pola-R-miniCHP) for 6 cycles, followed by 2 cycles of rituximab consolidation. Each cycle is 21 days.
Drugs: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Sites
1 site in 1 country
- The First Hospital of Jilin UniversityChangchun, Jilin, China